Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

Background Results from a phase III, randomized, double-blind, active comparator-controlled, parallel-group trial evaluating fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) found that a single-day, triple-antiemetic fosaprepitant regimen resulted in a significantl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC cancer Jg. 20; H. 1; S. 918 - 10
Hauptverfasser:	Weinstein, Cindy, Jordan, Karin, Green, Stuart, Khanani, Saleem, Beckford-Brathwaite, Elizabeth, Vallejos, Waldimir, Pong, Annpey, Noga, Stephen J., Rapoport, Bernardo L.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 25.09.2020 BioMed Central Ltd Springer Nature B.V BMC
Schlagworte:	Adult Aged Aged, 80 and over Anthracycline Anthracyclines Antiemetics - pharmacology Antiemetics - therapeutic use Aprepitant Biomedical and Life Sciences Biomedicine Breast cancer Cancer cancer burden and supportive therapy Cancer Research Cancer therapies Chemotherapy Chemotherapy-induced nausea and vomiting (CINV) Clinical trials Colorectal cancer Comparative analysis Cyclophosphamide Dexamethasone Dosage and administration Double-Blind Method Drug dosages Female Fosaprepitant Gastrointestinal cancer Glucocorticoids Gynecologic cancer Health Promotion and Disease Prevention Humans Intravenous administration Lung cancer Male Medicine/Public Health Middle Aged Morpholines - pharmacology Morpholines - therapeutic use Nausea Nausea - chemically induced Nausea - drug therapy Neoplasms - complications Oncology Prevention Research Article Subpopulations Surgical Oncology Survivorship Vomiting Vomiting - chemically induced Vomiting - drug therapy Young Adult Chemotherapy-induced nausea and vomiting (CINV) Breast cancer Fosaprepitant Gastrointestinal cancer Lung cancer Gynecologic cancer
ISSN:	1471-2407, 1471-2407
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!